Tazeen Ahmad
Stock Analyst at B of A Securities
(2.47)
# 2,328
Out of 4,876 analysts
207
Total ratings
47.1%
Success rate
-1.18%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $76 → $28 | $17.30 | +61.85% | 22 | Jun 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $201 → $216 | $174.37 | +23.87% | 10 | Jun 9, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $18 → $23 | $22.00 | +4.55% | 14 | Jun 5, 2025 | |
| PRTA Prothena Corporation | Downgrades: Underperform | $22 → $4 | $6.22 | -35.69% | 6 | May 28, 2025 | |
| STRO Sutro Biopharma | Maintains: Underperform | $1 → $0.8 | $0.79 | +0.82% | 3 | May 19, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $28 → $27 | $14.39 | +87.63% | 3 | May 19, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $41 → $23 | $17.92 | +28.38% | 7 | May 9, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Buy | $55 → $68 | $49.60 | +37.10% | 17 | May 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $63 → $68 | $61.73 | +10.16% | 8 | Apr 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $302 → $325 | $319.84 | +1.61% | 3 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $7.84 | +257.14% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $53.12 | +31.79% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $4.06 | +885.22% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $126.83 | +41.13% | 3 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $12.05 | +82.57% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.23 | +144.90% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $69.59 | +29.33% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $5.88 | +155.32% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $9.28 | -35.31% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $106.61 | +40.70% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $7.23 | -72.34% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $561.22 | +8.16% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $36.52 | +108.13% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $4.00 | +250.44% | 2 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.38 | +320.17% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.07 | +460.75% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $9.40 | +59.57% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $17.17 | -35.93% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $9.49 | +5.43% | 11 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $2.73 | -26.74% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.83 | +622.89% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $8.75 | +71.43% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $43.76 | +37.11% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.20 | +1,238.91% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $9.85 | +336.55% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $170.79 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $9.04 | +3,218.62% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.99 | +201.00% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $23.60 | +103.43% | 6 | Oct 10, 2018 |
Sarepta Therapeutics
Jun 16, 2025
Downgrades: Neutral
Price Target: $76 → $28
Current: $17.30
Upside: +61.85%
Ascendis Pharma
Jun 9, 2025
Maintains: Buy
Price Target: $201 → $216
Current: $174.37
Upside: +23.87%
ACADIA Pharmaceuticals
Jun 5, 2025
Maintains: Neutral
Price Target: $18 → $23
Current: $22.00
Upside: +4.55%
Prothena Corporation
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $6.22
Upside: -35.69%
Sutro Biopharma
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.79
Upside: +0.82%
Denali Therapeutics
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $14.39
Upside: +87.63%
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Neutral
Price Target: $41 → $23
Current: $17.92
Upside: +28.38%
PTC Therapeutics
May 9, 2025
Upgrades: Buy
Price Target: $55 → $68
Current: $49.60
Upside: +37.10%
Rhythm Pharmaceuticals
Apr 10, 2025
Maintains: Buy
Price Target: $63 → $68
Current: $61.73
Upside: +10.16%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Buy
Price Target: $302 → $325
Current: $319.84
Upside: +1.61%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $7.84
Upside: +257.14%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $53.12
Upside: +31.79%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $4.06
Upside: +885.22%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $126.83
Upside: +41.13%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $12.05
Upside: +82.57%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.23
Upside: +144.90%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $69.59
Upside: +29.33%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $5.88
Upside: +155.32%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $9.28
Upside: -35.31%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $106.61
Upside: +40.70%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $7.23
Upside: -72.34%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $561.22
Upside: +8.16%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $36.52
Upside: +108.13%
Apr 9, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $4.00
Upside: +250.44%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.38
Upside: +320.17%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.07
Upside: +460.75%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $9.40
Upside: +59.57%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $17.17
Upside: -35.93%
Jul 13, 2023
Upgrades: Buy
Price Target: $10
Current: $9.49
Upside: +5.43%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $2.73
Upside: -26.74%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.83
Upside: +622.89%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $8.75
Upside: +71.43%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $43.76
Upside: +37.11%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.20
Upside: +1,238.91%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $9.85
Upside: +336.55%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $170.79
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $9.04
Upside: +3,218.62%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.99
Upside: +201.00%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $23.60
Upside: +103.43%